XNAS · Healthcare · Biotechnology
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -0.02 | 0.01 | +150.00% | $15.1M | ✅ Beat | +4.87% | +7.90% | — |
| 2026-03-24 | Q4 2025 | 0.04 | -0.17 | -525.00% | $13.8M | ❌ Miss | -3.36% | +2.16% | +10.63% |
| 2025-11-13 |
| Q3 2025 |
| -0.05 |
| -0.02 |
| +60.00% |
| $12.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.04 | -0.11 | -175.00% | $9.7M | mixed | -1.32% | -4.22% | +2.70% |
| 2025-03-10 | Q4 2024 | -0.13 | -0.06 | +53.85% | $7.9M | ✅ Beat | +4.75% | +3.44% | -17.18% |
| 2024-11-07 | Q3 2024 | -0.10 | -0.21 | -110.00% | $7.0M | ❌ Miss | -1.61% | +0.92% | +38.99% |
| 2024-08-13 | Q2 2024 | -0.03 | -0.20 | -566.67% | $7.3M | ❌ Miss | -8.89% | -4.27% | -7.86% |
| 2024-05-14 | Q1 2024 | 0.26 | 0.41 | +57.69% | $25.4M | ✅ Beat | -4.90% | -3.00% | -6.27% |
Showing last 8 quarters.